Yatsenko L. D.

Drug Resistance of Malignant Neoplasms

About the author:

Yatsenko L. D.



Type of article:

Scentific article


The purpose of research was to review the current scientific concepts of the nature, mechanisms and factors of congenital and acquired drug resistance of malignant neoplasms to anticancer chemo drugs, particularly to platinum preparations, as well as finding the studies aimed at the destruction of cancer cells and increase of effectiveness of anticancer chemotherapy. The acquired chemo (and radio) resistance, increasing during the specific therapy, from course to course, is due to reactive, inducible increase of function of cell’s pre-existent protective systems. The more malignant neoplasm is, the less stable is the genotype of its cells, the more probable, that mutagenic effect of radiation- and chemotherapy will facilitate the selection and consolidation of more resistant genotypes. So, the А2780 line of ovarian carcinoma cells is sensitive to cys-platinum, while the A2780CR isogenic strain, obtaining on the mediums with increasing concentrations of cys-platinum, is more resistant by 20-30 times. Object and methods of research. In providing of antitumor chemo resistance several independent systems and mechanisms are engaged. In different cells of different tumors relative contribution of these mechanisms varies. The most studied systems of chemo resistance are the membrane Р-glycoprotein and group of membrane cassette proteins of multidrug resistance (MRP). Resistance to platinum preparations and other chemotherapeutic agents is also connected with specific cell mechanisms. Antiapoptotic mechanism also plays a significant role in the mechanism of chemo resistance. Doxorubicine- resistant cells (neuroblasts) produce antiapoptotic factors, reducing the activity of apoptisis’ enzymes (caspace-3) and DNA fragmentation. Four suppressive antiapoptotic factors, disturbing proteinase-A-regulatory path, included into mechanism of apoptosis, have been determined. The significant factor of detoxication and, consequently, increase of cells’ resistance to cytostatic agents’ effect, is intracellular content of thiolic compounds, first and foremost, GSH and dependent enzymes, as well as metallothioneins. Results of research and their discussion. Since the drug resistance is the major factor of low effectiveness of cancer chemotherapy, as efforts of scientists have been directing into its overcoming, first of all, elimination of effect of the most studied factors of resistance, i. e., Р-glycoprotein and proteins of multidrug resistance. Such inhibitors are of great variety, but the majority of them are toxic and increase antitumor drugs side effects. The search for selective, minimum toxic inhibitors of drug resistance was successful. MS-209 agent is the new quinolinic acid derivative, which directly interacts with proteins of multi resistance in the human stomach cancer cells with high expression of MDR. Another new BNP7787 non-toxic preparation is water soluble and effectively decreases total toxicity, renal toxicity and myelodepression, caused by platinum preparations, simultaneously increasing therapeutic effect of cys-platinum, allowing overcoming resistance to doxorubicine. Conclusions. Thus, the task of overcoming the neoplasms’ drug resistance due to inhibition of functions of membrane pumps of Р-glycoprotein and MRP-proteins is practically and clinically feasible


resistance, multidrug resistance, genes, P-glycoprotein, DNA preparation - genes and enzymes, reduced glutathione, glutathione S-reductases, inhibitors.


  • 1.    Тодор І. М. Вплив доксорубіцину в ліпосомальній формі на пухлини з фенотипом медикаментозної резистентності /
  • I.   М. Тодор, Н. Ю. Лук’янова, Ю. О. Тимовська // Онкология. Избранные лекции для студентов и врачей. - К.: Здоровье Украины,2010. - С. 569.
  • 2.    Чехун В. Ф. Способ лечения злокачественных опухолей, резистентних к химиотерапии / В. Ф. Чехун., Н. Ю. Лукьянова, В. М. Пивнюк [и др.] // Патент на полезную модель № 47929 от 25. 02. 2010.
  • 3.    Чехун В. Ф. Способ преодоления резистентности к лекарственному препарату «Доксорубицин» / В. Ф. Чехун, Д. Ю. Лукьянова, Д. В. Демаш. [и др.] // Патент на полезную модель №50922 от 25. 06. 2010.
  • 4.    Шалимов С. А. Лечение неоперабельных опухолей органов брюшной полости / С. А. Шалимов, Л. В. Кейсевич, А. А. Литвиненко [и др.]. - Киев : Пресса Украины, 1998. - 252 с.
  • 5.    Chehun V. F. The lipid content of cisplatin- and doxorubicin-resistant MCF-7 human breast cancer cells / I. N. Todor, N. Yu. Lukyanova. // Exp. Oncology. - 2012. - Vol. 34, № 2. - P. 97-100.
  • 6.    Chekhun V. F. The role of expression of the components of proteome in the formation of molecular profile of human ovarian carcinoma A2780 cells sensitive and resistant to cisplatin / V. F Chekhun, N. Yu. Lukyanova, O. V. Yurchenko [et al.] // Exp. Oncol. - 2005. - Vol. 27. - P. 191-195.
  • 7.    Chekhun VF Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells / V. F Chekhun, G. I. Kulik, O. V. Yurchenko [et al.] //Cancer Letters. - 2006. - Vol. 231. - P. 87-93.
  • 8.    Cheung N. -K. V. Neuroblastoma: developmental biology, cancer genomics and immunotherapy / N. -K. V. Cheung, M. A. Dyer. // Nature reviews. Cancer. - 2013. - Vol. 13. - P. 397-411.
  • 9.    Davoli T. The Causes and Consequences of Polyploidy in Normal Development and Cancer / Т. Davoli // Ann. Rev. Cell Dev. Biol . - 2011. - Vol. 27. - R 585-610.
  • 10.   DeBartolo J. Predictive Bcl-2 family binding models rooted in experiment or structure / J. DeBartolo, S. Dutta, L. Reich // Biol. - 2012. - Vol. 422(1). - R 124-144.
  • 11.   DeBartolo J. Immunoexpression of cell cycle biomarkers in neuroblastoma samples and its correlation with prognostic factors
  • J.   Bras / J. DeBartolo, S. Dutta, L. Reich [et al.] // Patol. Med. Lab. - 2013. - Vol. 49(1). - P. 57-63.
  • 12.   Goldhirsch A. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer / W. C. Wood, A. S. Coates [et al.] // Ann. Oncol. - 2011. - Vol. 8(22). - R 1736-1747.
  • 13.   Holland A. J. Losing balance: the origin and impact of aneuploidy in cancer / A. J. Holland, D. W. Cleveland // EMBO. - 2012. - Vol. 13(6). - P. 501-514.
  • 14.   Li Y. Apoptotic Cell Death in Neuroblastoma /Y Li, A. Nakagawara // Cells. - 2013. - Vol. 2. - R 432-459.
  • 15.   Liu H. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers / H. Liu, Q. Fan, Z. Zhang [et al.] //Hum. Pathol. - 2008. - Vol. 2 (39). - R 167-174.
  • 16.   Lukyanova N. Yu. Molecular profile an cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin / N. Yu. Lukyanova // Exp. Oncology. - 2012. - Vol. 34, № 2. - P. 97-100.
  • 17.   Shi Y HDM2 impairs Noxa transcription and affects apoptotic cell death in a p53/p73-dependent manner in neuroblastoma / Y Shi, H. Takenobu, K. Kurata [et al.] // Eur. J. Cancer. - 2010. - Vol. 46(12). - R 2324-2334.
  • 18.   Speleman F Neuroblastoma genetics and phenotype: a tale of heterogeneity / F. Speleman, K. De Preter, J. Vandesompele // Semin. Cancer Biol. - 2011. - Vol. 21(4). - R 238-244.
  • 19.   Todor I. N. The lipid content of cisplatin- and doxorubicin-resistant MCF-7 human breast cancer cells / I. N. Todor, N. Yu. Lukyanova // Exp. Oncology. - 2012. - Vol. 34, № 2. - P. 97-100.
  • 20.   Tikhmyanova N. CAS proteins in normal and pathological cell growth control / N. Tikhmyanova, J. L. Little, E. A. Golemis // Cell Mol. Life Sci. - 2010. - Vol. 67. - P. 1025-1048.

Publication of the article:

«Bulletin of problems biology and medicine» Issue 1 (106), 2014 year, 41-44 pages, index UDK 616-006:615. 28